Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Journal of Molecular Biology
|
October 26, 1999
Roles for glycosylation of cell surface receptors involved in cellular immune recognition
P M Rudd, M R Wormald, R L Stanfield, et al.
Molecular Psychiatry
|
February 20, 2013
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4
U Andreasson, R Lautner, J M Schott, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 6, 2021
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
A Leuzy, N J Ashton, N Mattsson-Carlgren, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 7, 2021
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
N J Ashton, A Leuzy, T K Karikari, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 21, 2009
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
N Mattsson, M Axelsson, S Haghighi, et al.
Neurology
|
February 4, 2012
Age and diagnostic performance of Alzheimer disease CSF biomarkers
N Mattsson, E Rosén, O Hansson, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Journal of Molecular Biology
|
October 26, 1999
Roles for glycosylation of cell surface receptors involved in cellular immune recognition
P M Rudd, M R Wormald, R L Stanfield, et al.
Molecular Psychiatry
|
February 20, 2013
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4
U Andreasson, R Lautner, J M Schott, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 6, 2021
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
A Leuzy, N J Ashton, N Mattsson-Carlgren, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 7, 2021
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
N J Ashton, A Leuzy, T K Karikari, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 21, 2009
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
N Mattsson, M Axelsson, S Haghighi, et al.
Neurology
|
February 4, 2012
Age and diagnostic performance of Alzheimer disease CSF biomarkers
N Mattsson, E Rosén, O Hansson, et al.
Page
of 2